Safety and Efficacy of GFB-887, a TRPC5 Channel Inhibitor, in Patients With Focal Segmental Glomerulosclerosis, Treatment-Resistant Minimal Change Disease, or Diabetic Nephropathy: TRACTION-2 Trial Design

Autor: Walsh, Liron, Reilly, John F., Cornwall, Caitlin, Gaich, Gregory A., Gipson, Debbie S., Heerspink, Hiddo J.L., Johnson, Leslie, Trachtman, Howard, Tuttle, Katherine R., Farag, Youssef M.K., Padmanabhan, Krishna, Pan-Zhou, Xin-Ru, Woodworth, James R., Czerwiec, Frank S.
Zdroj: In Kidney International Reports October 2021 6(10):2575-2584
Databáze: ScienceDirect